David V. Goeddel Buys 135,688 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYAGet Rating) Director David V. Goeddel bought 135,688 shares of the company’s stock in a transaction that occurred on Wednesday, January 18th. The shares were bought at an average cost of $2.52 per share, for a total transaction of $341,933.76. Following the transaction, the director now directly owns 9,800,535 shares of the company’s stock, valued at approximately $24,697,348.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Tenaya Therapeutics Stock Performance

Shares of TNYA stock opened at $2.86 on Friday. The firm has a fifty day moving average of $2.28 and a 200-day moving average of $3.40. The stock has a market cap of $118.33 million, a price-to-earnings ratio of -1.02 and a beta of 1.61. Tenaya Therapeutics, Inc. has a 52-week low of $1.64 and a 52-week high of $16.17.

Tenaya Therapeutics (NASDAQ:TNYAGet Rating) last posted its earnings results on Thursday, November 10th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). On average, sell-side analysts predict that Tenaya Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Canaccord Genuity Group began coverage on shares of Tenaya Therapeutics in a research report on Monday, November 7th. They issued a “buy” rating on the stock. Canaccord Genuity Group started coverage on Tenaya Therapeutics in a research report on Tuesday, November 8th. They set a “buy” rating and a $21.00 target price on the stock. Finally, Chardan Capital cut their price target on Tenaya Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a report on Friday, November 11th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $24.67.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of hedge funds have recently modified their holdings of TNYA. Woodline Partners LP grew its position in Tenaya Therapeutics by 434.2% in the second quarter. Woodline Partners LP now owns 200,698 shares of the company’s stock valued at $1,130,000 after acquiring an additional 163,130 shares during the period. SG Americas Securities LLC bought a new stake in shares of Tenaya Therapeutics in the 2nd quarter worth about $59,000. Amalgamated Bank acquired a new stake in shares of Tenaya Therapeutics during the 1st quarter worth about $29,000. Two Sigma Investments LP bought a new position in Tenaya Therapeutics during the 3rd quarter valued at about $97,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Tenaya Therapeutics in the third quarter valued at about $69,000.

About Tenaya Therapeutics

(Get Rating)

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).

See Also

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.